Tuesday, November 3, 2026

Back to today

Stevanato down 30%. Yikes.

Stevanato fell 30% after forecasting low-single-digit 2027 growth as lower Nexa syringe volumes from a GLP-1 customer offset solid Q3 margins and non-GLP biologics demand.

From X

@StableBread 1 click

Fajasy on X

My bear, base, and bull cases value Boost Run’s $BRUN stock on year-end 2026 ARR (on the same basis as the multiples of CoreWeave $CRWV, Nebius $NBIS, and $IREN), which $BRUN will report with its Q4 results in March 2027. None of the three cases adds the $160.7M/year from the July order and Cohere, since both start in 2027. The peers’ contracts that start after 2026 aren’t in their year-end ARR either, so they’re priced into the multiples instead. Since the peers’ multiples leave out the debt they’ll take on to reach year-end ARR, I hold $BRUN’s net debt at today’s $244.3M, rather than adding the lease debt from its H2 2026 build. Each case’s value is year-end ARR times the multiple, minus the $244.3M of net debt, divided by the 88.8M fully diluted shares plus any new shares from a stock sale. I start with the $231.4M of ARR from contracts already running, then add (1) the June order’s $69.2M/year if it starts by December 31 and (2) however much of the $99.4M from contracts without disclosed terms is running by then. Bear case ($4.76, -46%) The bear case assumes $BRUN has no new financing to show by its Q3 report, lessors fund 70% of the H2 2026 build instead of 79.5% (below the 72.0% lessors funded in 2025), and the June order’s November 30 start slips into 2027, so 2026 GPU spending stays at the $1.0B low end of management’s range. That implies year-end ARR of $280M, 30% short of the target, a $62.2M stock sale at $8.89/share (7.0M new shares) to cover the funding gap and three months of 2027 payments, and today’s 2.5x, for a value of $4.76/share. I give the bear case about a 20% chance. Base case ($16.17, +82%) The base case assumes $BRUN lands new lease or asset-backed financing by year-end, starts the June order on November 30, and reaches its $400M target without selling stock. That implies $400M of year-end ARR at CoreWeave’s 4.2x, the median of the three peers, for a value of $16.17/share. I use today’s median, since the base case only solves $BRUN’s own financing problem. It assumes no relief on rates or borrowing costs, which would lift the peers’ multiples too. Bull case ($19.78, +122%) The bull case assumes everything in the base case, plus relief on rates and borrowing costs that lifts the peers’ multiples. That implies $400M of year-end ARR at 5.0x, still below Nebius’s 5.9x, for a value of $19.78/share. So the bull case is really a bet on the market, not on anything more from $BRUN. From $8.89/share, you’re risking a $4.13 loss (-46%) in the unlikely bear case for a $10.89 gain (+122%) in the more likely bull case. P.S. These cases use the October 16 close and predate $BRUN’s October 26 release, which says it has closed more than $600M of non-dilutive project financing in 2026.

Initiation Report

Nine Mile Metals is initiated under research coverage.

When the liquidity does not add up

Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…

Verra veerer

Verra Mobility’s Avis termination threatens 2027 earnings, while Government Solutions profit rose 25% and implied fourth-quarter guidance…

PRIM · long

Primoris Services CORP

Primoris Services, a $5 billion EPC contractor, has fallen about 60% from its peak.

OSS Q3 FY12/26 Earnings Analysis

One Stop Systems grew Q3 continuing-operations revenue 36% to $12.6 million, raised FY2026 revenue guidance to $45 million, and used $11.8…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

288 firms

Sectors

Ordered by how often our editor reaches for them.